Revvity Inc
F:PKN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
R
|
Revvity Inc
F:PKN
|
US |
|
North Energy ASA
F:RN2
|
NO |
Intrinsic Value
The intrinsic value of Revvity Inc (PKN) under the Base Case is 106.16 EUR per share. Compared with the current market price of 140.15 EUR, the stock appears Overvalued by 24% .
The intrinsic value is the average of valuations using the DCF method and multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Revvity Does
Revvity makes tools and tests used in laboratories that study biology and diagnose disease. Its products include laboratory instruments, reagents, assay kits, software, and related services that help customers measure biological signals, run genetic and biochemical tests, and analyze results. The company serves drug developers, biotech and academic research labs, and clinical and public health laboratories.
- Headquarters
- United States of America US
- Employees
- 11 000
- IPO date
- Jul 6, 1965
Revvity has no economic moat
Customers can choose among many suppliers because research tools and diagnostic products compete on price, service, technology, availability, quality and reliability—not because a supplier’s product becomes more valuable as more labs use it. Revvity’s patents and product names support particular offerings, but its disclosures do not show a company-wide lock on customers or a brand premium that keeps rivals from competing.
Read the full moat analysis
Revenue & Expenses Breakdown
Revvity Inc
Earnings Waterfall
Revvity Inc
The intrinsic value for Revvity Inc (PKN) under the Base Case is 106.16 EUR.
Compared with the current market price of 140.15 EUR, the stock appears Overvalued by 24% .